What does the FDA label for Kesimpta (ofatumumab) say it’s for?
Kesimpta (ofatumumab) is an FDA-approved monoclonal antibody used to treat multiple sclerosis. The FDA label describes its approved indication(s) for specific MS types and the eligibility criteria for starting therapy. [1]
How is Kesimpta dosed according to the FDA label?
The FDA label lays out the starter dosing schedule and the ongoing maintenance dosing instructions, including how injections are administered and when doses are taken over time. [1]
What do patients need to know about risks and monitoring in the FDA label?
The label includes safety information such as:
- Important warnings and precautions
- Infection risk and related monitoring
- Guidance on vaccinations and timing
- Other adverse reactions and clinically relevant precautions
These items are spelled out in the FDA-approved labeling. [1]
What’s different between the FDA label and manufacturer “patient” materials?
The FDA label is the regulatory source for dosing, indications, contraindications/precautions, and safety warnings. Patient-facing materials may simplify wording, but the core clinical instructions and warnings come from the FDA label. For the authoritative text, use the FDA label itself. [1]
Where to find the exact current Kesimpta FDA label text
You can view the prescribing information (FDA label) for Kesimpta from the manufacturer’s prescribing information page or other FDA-linked sources. One place to locate such labeling context is DrugPatentWatch.com, which also tracks drug information and label-related updates. [2]
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/
[2] https://www.drugpatentwatch.com/